CATEGORY: BRAIN & MENTAL HEALTH
Many people with migraine get a few hours’ notice: fatigue, a stiff neck, light that suddenly hurts. In a randomized US trial, adults who took the drug ubrogepant during those warning hours escaped moderate or severe headache over the next 24 hours after 46% of treated episodes, against 29% when they had unknowingly swallowed a placebo instead.1
Intercepting the Messenger Before the Alarm
That opening act is called the prodrome. It is a stretch of warning symptoms, among them tiredness, neck stiffness, trouble concentrating, sensitivity to light or sound, yawning and food cravings, and in many people it reliably ends in head pain within a few hours. Ubrogepant is a tablet already used once the pain has arrived. It blocks CGRP, a chemical messenger nerve cells release during a migraine to turn pain signaling up. Picture intercepting the messenger on the road rather than waiting for the alarm to sound. The trial asked whether blocking it early could keep the headache from showing up at all.1
Each Person Answered the Question Twice
Researchers enrolled 518 adults, aged 18 to 75, who had lived with migraine for at least a year and could tell dependably when an attack was coming. Each treated two separate warning episodes. One got a single 100-milligram ubrogepant tablet, the other an identical-looking placebo, in an order nobody involved could see or choose. Every participant therefore served as his or her own comparison: same brain, same disease, two differently treated warnings. That filters out much of the person-to-person variation that muddies migraine research. In the end 477 people treated qualifying episodes and entered the analysis, with each episode followed for 48 hours.1
One Warning in Two, Not Every Warning
Treated with ubrogepant, 46% of episodes produced no moderate or severe headache within 24 hours, 190 of 418. On placebo the figure was 29%, or 121 of 423. The gap held across the full two days, 41% versus 25% of episodes staying clear through 48 hours. The flip side is plain enough: most treated warnings still ended in a bad headache. The tablet moved the odds of escaping one from roughly one in three to nearly one in two. It did not switch attacks off. Side effects within 48 hours ran modestly higher on the drug, 17% of episodes versus 12%, and were mostly nausea, fatigue or dizziness. A later analysis of the same trial followed the warning symptoms themselves. Treated episodes were more often free of neck pain three hours after the dose (28.9% versus 15.9%), free of sound sensitivity at four hours (50.7% versus 35.8%), and free of light sensitivity at two hours (19.5% versus 12.5%).2 Those figures are exploratory rather than definitive. One boundary deserves stating: only people who could recognize their own warning signs dependably were enrolled, and some attacks arrive with no usable warning at all.1
Key Takeaways
- Taking ubrogepant during the warning phase left 46% of episodes free of moderate or severe headache over 24 hours, versus 29% with placebo, and 41% versus 25% over 48 hours, in a randomized crossover trial of 477 US adults.
- Most treated warning episodes still ended in a bad headache. What changed was the chance of escaping one, from about one in three to nearly one in two.
- Participants had to demonstrate before enrolling that they could recognize their own warning symptoms, so the finding speaks to that group.
- Side effects ran modestly higher on the drug, 17% versus 12% of episodes, mostly nausea, fatigue or dizziness.
References
- Dodick DW, Goadsby PJ, Schwedt TJ, et al. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA. The Lancet. 2023;402(10419):2307–2316. link
- Goadsby PJ, Ailani J, Dodick DW, et al. Ubrogepant for the treatment of migraine prodromal symptoms: an exploratory analysis from the randomized phase 3 PRODROME trial. Nature Medicine. 2025;31(7):2179–2185. link